RA Chem Pharma Limited

RA Chem Pharma Limited, established on January 8, 1996, is a publicly held Indian pharmaceutical company headquartered in Hyderabad, Andhra Pradesh. The company is registered under the Corporate Identification Number (CIN) U24110TG1996PLC022816. As of the latest available data, RA Chem Pharma has an authorized capital of ₹140 crore and a paid-up capital of ₹85.01 crore, reflecting a paid-up capital percentage of approximately 60.72%. The company operates in the manufacturing sector, focusing on chemicals and chemical products. RA Chem Pharma Limited is not listed on any stock exchange.

Over the past 15 years, RA Chem Pharma has expanded its operations by establishing fully cGMP-compliant manufacturing facilities, state-of-the-art research and development (R&D) centers, and a clinical research facility. The company's product portfolio includes active pharmaceutical ingredients (APIs), solid dosage formulations, and clinical studies, catering to various therapeutic categories.

RA Chem Pharma Limited operates multiple manufacturing facilities across India. The company has a cGMP-compliant API manufacturing plant located in Jaggayapet, Krishna District, Andhra Pradesh. Additionally, it has a cGMP-compliant solid dosage formulation manufacturing facility at Nacharam, Hyderabad, and a GCP and GLP-compliant clinical research and biosciences division at Balanagar, Hyderabad.

The leadership team at RA Chem Pharma Limited comprises several key executives. Rajender Rao Juvvadi serves as a director, while Pritam Amir Singh, Ravula Sirish Kumar, Ravi Kumar Yerra, and Srinivasa Reddy Battula also hold directorial positions. The company's leadership is known for its visionary approach, technological competence, and commitment to research innovation.

RA Chem Pharma Limited has made significant strides in obtaining regulatory approvals for its products in various international markets. The company's manufacturing facilities hold international accreditations, including those from the US FDA, EDQM, ANSM (France), WHO (Geneva), TGA (Australia), and MFDS (Korea). These certifications enable RA Chem Pharma to export its products to regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory standards ensures the quality and safety of its pharmaceutical products in these markets.

RA Chem Pharma Limited has expanded its presence in emerging markets, including regions in Africa, Latin America, Southeast Asia, and South Asia. The company's international accreditations, such as those from the WHO (Geneva), facilitate access to these markets. By leveraging its manufacturing capabilities and regulatory compliance, RA Chem Pharma aims to meet the growing demand for quality pharmaceutical products in these regions.

RA Chem Pharma Limited's geographic strategy involves diversification across various international markets, including both regulated and emerging regions. The company's international accreditations and compliance with global regulatory standards enable it to mitigate concentration risks associated with dependence on a single market. This strategic approach positions RA Chem Pharma to capitalize on global opportunities and maintain a competitive edge in the pharmaceutical industry.

RA Chem Pharma Limited's manufacturing facilities are registered with the US Food and Drug Administration (FDA), indicating compliance with FDA regulations. The company has filed Drug Master Files (DMFs) for over 50 APIs across diverse therapeutic categories, including antifungals, antipsychotics, NSAIDs, anti-allergy agents, antiparkinsons, anticonvulsants, antidepressants, antispasmodics, and animal feed additives. This extensive filing demonstrates RA Chem Pharma's commitment to meeting the stringent requirements of the FDA and underscores its capability to supply quality pharmaceutical products to the US market.

RA Chem Pharma Limited's manufacturing facilities hold certifications from the World Health Organization (WHO) and the European Directorate for the Quality of Medicines & HealthCare (EDQM). These certifications attest to the company's adherence to international Good Manufacturing Practices (GMP) standards. The WHO prequalification and EU GMP certificates enable RA Chem Pharma to supply pharmaceutical products to international markets, including those in Europe and other regions that recognize these certifications.

RA Chem Pharma Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facilities are compliant with CDSCO regulations, ensuring the quality and safety of its pharmaceutical products. Additionally, RA Chem Pharma has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating the export of its products to international markets.

As of the latest available information, there are no publicly disclosed records of Form 483 observations, warning letters, or import alerts issued to RA Chem Pharma Limited by regulatory authorities. The company's adherence to international regulatory standards and its commitment to quality manufacturing practices contribute to its positive regulatory standing.

RA Chem Pharma Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. Its focus on manufacturing APIs and solid dosage formulations, along with its international accreditations, positions it favorably in the market. The company's commitment to quality, regulatory compliance, and customer support enhances its competitive edge. However, the pharmaceutical industry is dynamic, and RA Chem Pharma must continuously innovate and adapt to maintain its market position.

RA Chem Pharma Limited's key differentiators include its vertically integrated operations, encompassing API manufacturing, solid dosage formulations, and clinical research. The company's state-of-the-art manufacturing facilities and dedicated R&D infrastructure support its ability to develop and manufacture a diverse range of pharmaceutical products. International accreditations from regulatory bodies such as the US FDA, EDQM, ANSM (France), WHO (Geneva), TGA (Australia), and MFDS (Korea) underscore the company's commitment to quality and regulatory compliance.

RA Chem Pharma Limited's current strategic direction focuses on maintaining its position as a vertically integrated pharmaceutical company. The company's operations span API manufacturing, solid dosage formulations, and clinical research, enabling it to offer end-to-end solutions to its customers. Looking ahead, RA Chem Pharma aims to leverage its manufacturing capabilities and regulatory compliance to expand its presence in both regulated and emerging markets, ensuring sustainable growth and competitiveness in the global pharmaceutical industry.

RA Chem Pharma Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a commitment to quality. The company's export volume and consistency are supported by its international accreditations and compliance with global regulatory standards. Reliability indicators include its adherence to cGMP, GCP, and GLP standards, as well as its history of successful regulatory approvals. These factors contribute to RA Chem Pharma's reputation as a dependable supplier in the pharmaceutical industry.

Importers should verify the following certifications when considering RA Chem Pharma Limited as a supplier:

• FDA Registration: Confirm the company's registration status with the US FDA to ensure compliance with US regulations.

• WHO-GMP Certification: Verify the WHO Good Manufacturing Practices certification to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU Good Manufacturing Practices certification to confirm compliance with European quality standards.

• ISO Certifications: Review any ISO certifications held by the company to assess its commitment to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from RA Chem Pharma Limited.

When conducting due diligence on RA Chem Pharma Limited, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Manufacturing Facilities: Evaluate the compliance of manufacturing facilities with cGMP, GCP, and GLP standards.

• Review Financial Statements: Analyze the company's financial health through audited financial statements.

• Check Regulatory Compliance History: Investigate any past regulatory actions, such as warning letters or import alerts.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain operations.